Intuitive Surgical Fell 30% in 2026 as a Rival Arrived. Here’s Where the Stock Could Go

Category: Markets

Published: 2026-08-17T16:11:38.000Z

Intuitive Surgical (ISRG) stock fell 30% in 2026, primarily due to the FDA clearance of Johnson & Johnson’s Ottava robot, introducing a significant rival in soft-tissue surgery. Despite the competitive threat, ISRG reported a 19% revenue increase, but management's decision not to raise full-year guidance after a strong Q2 contributed to the stock's decline. The article suggests that the key to future performance lies in U.S. da Vinci procedure growth and how quickly the new competitor gains market share, urging investors to watch Q3 results.

Read the original source

News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.